The importance of platelet derived tissue factor pathway inhibitor in coagulatio

Recruiting

• Conditions: gezonde proefpersonen, fysiologie; coagulation thrombosis; 10064477; 10011082

• Registration Number: NL-OMON37601
• Lead Sponsor: niversiteit Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 38

Inclusion Criteria

age 18-55 years old
written informed consent

Exclusion Criteria

use of anticoagulant agents (such as heparin, vitamin K antagonists)
use of aspirine, clopidogrel or non steroidal anti-inflammatory drugs within 2 weeks prior to the study

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameters are the peak height of the thrombin generation curve<br /><br>in plasma obtained from non activated platelet rich plasma (PRP) compared with<br /><br>the peak height of the thrombin generation curve in plasma obtained from<br /><br>activated PRP by T different agonists. Thrombin generation will be determined<br /><br>under different assay conditions:<br /><br>triggered with low and hihg TF concentrations<br /><br>in the absence and presence of anti-TFPI antibodies and anti protein S<br /><br>antibodies. In 8 healhty volunteers different available TFPI tests will be<br /><br>performed. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>TFPI elisa and protein S elisa in plasma obtained from non activated platelet<br /><br>rich plasma (PRP) compared with the peak height of the thrombin generation<br /><br>curve in plasma obtained from activated PRP activated by platelet agnostists.<br /><br>western blot, flow cytometry, activity assays. </p><br>